Amivantamab in METex14+ NSCLC
Phase I CHRYSALIS Update: Amivantamab in Expanded Cohort of Patients With Advanced NSCLC and MET Exon 14 Skipping Mutations

Released: September 20, 2023

Activity

Progress
1
Course Completed